vTv Therapeutics Inc.
VTVT · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D44Clinical/early-stage biotech — diabetes/metabolic clinical, very well-funded.
Strengths
- Liquidity — current ratio 13.5 (88th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Revenue declineRevenue -100.0% YoY
- Notable holderHeld by 3 notable fund(s): FMR LLC, GOLDMAN SACHS GROUP INC, STATE STREET CORP (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: STATE STREET CORP
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-41.9%
Return on assets
-30.0%
Revenue growth (QoQ)
-100.0%
Current ratio
13.5×
Tangible book value
$64M
Cash & investments
$89M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-09-22 | AKKARAJU SRINIVAS | Grant | 106K | $15.27 |
| 2025-09-03 | BAKER BROS. ADVISORS LP | Grant | 4.3K | — |
| 2025-09-03 | BAKER BROS. ADVISORS LP | Grant | 47K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-13 | 2026-05-13 | 0001641489-26-000019 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001193125-26-221971 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001641489-26-000020 ↗ |
| 8-K | 2026-03-10 | 2026-03-10 | 0001641489-26-000012 ↗ |
| 8-K | 2026-03-10 | 2026-03-10 | 0001641489-26-000011 ↗ |
| 10-K | 2026-03-10 | 2025-12-31 | 0001641489-26-000010 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001641489-26-000005 ↗ |
| 8-K | 2026-02-02 | 2026-01-30 | 0001641489-26-000002 ↗ |
| 8-K | 2025-12-19 | 2025-12-19 | 0001641489-25-000066 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001641489-25-000060 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001641489-25-000058 ↗ |
| 8-K | 2025-09-10 | 2025-09-10 | 0001641489-25-000055 ↗ |